Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI – Get Free Report)’s share price shot up 1.3% during mid-day trading on Friday . The stock traded as high as $0.18 and last traded at $0.16. 1,103,124 shares were traded during trading, an increase of 5% from the average session volume of 1,049,327 shares. The stock had previously closed at $0.16.
Analyst Ratings Changes
Several research firms recently commented on CLDI. HC Wainwright decreased their target price on Calidi Biotherapeutics from $11.00 to $2.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. Robert W. Baird dropped their target price on Calidi Biotherapeutics from $9.00 to $4.50 and set an “outperform” rating on the stock in a report on Thursday, March 21st.
Get Our Latest Analysis on Calidi Biotherapeutics
Calidi Biotherapeutics Stock Performance
About Calidi Biotherapeutics
Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.
Recommended Stories
- Five stocks we like better than Calidi Biotherapeutics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Comprehensive Analysis of PayPal Stock
- Why Invest in High-Yield Dividend Stocks?
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
